Marker Therapeutics, Inc. revenue breakdown overview

Marker Therapeutics, Inc. revenue for the last year amounted to 3.31 M USD, the most of which — 3.31 M USD — came from its highest performing source at the moment, Immunotherapies and Innovative Peptide-Based Vaccines, the year earlier bringing 9.01 M USD. The greatest contribution to the revenue figure was made by United States — last year it brought Marker Therapeutics, Inc. 3.31 M USD, and the year before that — 9.01 M USD.